Tag: Functional Improvement
Novel approach also shows promise for autoimmune diseases
Paralyzing damage in spinal cord injury (SCI) is often caused by the zealous immune response to the injury. NIBIB-funded engineers have developed nanoparticles that lure immune cells away from the spinal cord, allowing regeneration that restored spinal cord function in mice.
Researchers from Australia have successfully “rewired” the nerves within the paralyzed arms of some accident survivors and provided them with successful movement of arms and hands.
The results of the study titled, “Expanding traditional tendon-based techniques with nerve transfers for the restoration of upper limb function in tetraplegia: a prospective case series”, were published in the latest issue of the Lancet.
A systemically injectable peptide, which may make it possible to restore lost functions in spinal cord injury patients, is moving toward clinical trials in early 2020.
The treatment, which was developed by Jerry Silver, a professor of neurosciences at Case Western Reserve University’s School of Medicine and advisor for NervGen Pharma, is the culmination of decades of work, and in pre-clinical studies, it has shown robust results in animal models.
Spinal cord injury (SCI) commonly results in paralysis from the injury site down, even when the spinal cord hasn’t been severed completely. The remaining nerve cells that might bridge the gap appear to switch off, resulting in total loss of muscle control and sensation. Scientists at Boston Children’s Hospital have now identified a small molecule drug that effectively reactivates the signaling pathways between these remaining nerve cells and the brain, restoring walking ability in mice that had been paralyzed by SCI.
After suffering a severe cervical spinal cord injury from a bad fall at work, Scott McConnell had little function remaining in his hands and arms.
Today the Epidural Stimulation Procedure brings new hope for Patients with Spinal Cord Injury.
Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side
FREMONT, Calif., June 13, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) patients have now recovered two levels of motor function and previously-announced improvements in arm, hand and finger function at 3-months and 6-months following administration of AST-OPC1 have been confirmed and further increased at 9-months.
A new discovery at the University of Alberta will fundamentally alter how we view spinal cord function and rehabilitation after spinal cord injuries (SCI). Neuroscientists found that spinal blood flow in rats was unexpectedly compromised long after a spinal cord injury (chronically ischemia), and that improving blood flow or simply inhaling more oxygen produces lasting improvements in cord oxygenation and motor functions, such as walking.
Previous work had shown that while blood flow was temporarily disrupted at the injury site, it resumed rapidly, and it was more or less assumed that the blood flow was normal below the injury. This turns out to be wrong.
Tendon transfer can significantly improve hand and elbow function in quadriplegic patients, but the procedure is greatly underused, according to a new study.
A review of studies by hand surgeon Professor Michael Bednar, MD, of Loyola Medicine (Maywood, IL, USA) found that an estimated 65-75% of patients with cervical spinal cord injuries could benefit from upper extremity tendon transfer surgery, but only 14% of patients actually complete the procedure. Tendon transfer surgically redirects functional muscles to do the work of muscles that are paralyzed. Depending on the extent of the spinal cord injury, tendon transfers can enable a patient to grasp objects, pinch, open the hand, and straighten the elbow.
Three years ago, Michael Fraser broke his neck in a diving accident near his Vandergrift home but remembers little about it.
But in April, the man with quadriplegia underwent an experimental neural stem-cell procedure that wasn’t only a life-changing experience but could represent the first interventional treatment for spinal cord injuries.
Mr. Fraser, 24, now can lift himself from his wheelchair into bed without assistance. He breathes more freely and deeply and has greater core strength with better dexterity. Previously he could manage only a half-mile on his arm-powered elliptical but now does two to three miles, he said.